Clinical Trial Update: Dose Finding Safety Study of VAL201 in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A dose-finding safety study of VAL201 in prostate cancer patients has completed Phase 1/Phase 2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Carcinoma

Drugs mentioned

• VAL201

Snippet

Sponsor: ValiRx Plc | Conditions: Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-08